BioSyent logo.png
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
September 20, 2024 09:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has...
BioSyent logo.png
BioSyent Releases Financial Results for Q2 and H1 2024
August 26, 2024 16:45 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30,...
BioSyent logo.png
BioSyent Declares Third Quarter 2024 Dividend
August 26, 2024 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent In-Licenses Endocrinology Product for Canada
June 12, 2024 09:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent logo.png
BioSyent Releases Financial Results for Q1 2024
May 16, 2024 18:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights...
BioSyent logo.png
BioSyent Declares Second Quarter 2024 Dividend
May 16, 2024 18:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend...
BioSyent logo.png
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024
May 09, 2024 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on...
BioSyent logo.png
BioSyent to Attend Planet MicroCap Showcase
April 23, 2024 17:45 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas,...
BioSyent logo.png
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
April 15, 2024 16:31 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent logo.png
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024 08:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton &...